Table 1.

Studies evaluating the potential prognostic significance of TET2 mutations in patients with myeloid malignancies

Disease	Reference	Patients studied	Prognostic relevance
AML	(Abdel-Wahab et al., 2009)	119 AML patients including de novo AML, therapy-related AML, and AML with an antecedent hematologic disorder	TET2 mutations were associated with significantly worsened overall survival.
AML	(Nibourel et al., 2010)	111 patients with de novo AML	TET2 mutations did not impact overall survival.
AML	(Metzeler et al., 2011)	427 patients with normal karyotype AML	TET2 mutations were associated with a lower complete remission rate and shorter disease free and overall survival.
Secondary AML	(Kosmider et al., 2011)	247 patients with AML derived from MDS or therapy-related AML	TET2 mutations did not influence complete remission rates or overall survival.
MDS	(Kosmider et al., 2009a)	89 MDS patients and 7 with MDS transformed to AML	TET2 mutations associated with a significantly improved overall and progression-free survival.
MDS	(Bejar et al., 2011)	439 de novo MDS patients	TET2 mutations did not impact overall survival or effect clinical characteristics in an adverse way.
MPN	(Tefferi et al., 2009)	239 BCR-ABL negative MPN patients	TET2 mutations did not impact overall survival or effect clinical characteristics in an adverse way.
CMML	(Kosmider et al., 2009b)	88 patients with CMML	TET2 mutations strongly associated with monocytosis. In the overall cohort, TET2 mutations did impact survival but TET2 imparted significantly worse overall survival in patients with CMML I specifically.